Evidence map›Paper›PMID 39773984›Full record

ArticleNature communications2025

Endothelial-secreted Endocan activates PDGFRA and regulates vascularity and spatial phenotype in glioblastoma.

Soniya Bastola, Marat S Pavlyukov, Neel Sharma, Yasmin Ghochani, Mayu A Nakano, Sree Deepthi Muthukrishnan, Sang Yul Yu, Min Soo Kim, Alireza Sohrabi, Natalia P Biscola and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Soniya Bastola *The Intellectual and Developmental Disabilities Research Center, The Semel Institute for Neuroscience and Human Behavior, and The Broad Stem Cell Research Center, The Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-0236-5540
Marat S Pavlyukov *The Intellectual and Developmental Disabilities Research Center, The Semel Institute for Neuroscience and Human Behavior, and The Broad Stem Cell Research Center, The Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Neel SharmaThe Intellectual and Developmental Disabilities Research Center, The Semel Institute for Neuroscience and Human Behavior, and The Broad Stem Cell Research Center, The Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Yasmin GhochaniThe Intellectual and Developmental Disabilities Research Center, The Semel Institute for Neuroscience and Human Behavior, and The Broad Stem Cell Research Center, The Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Mayu A NakanoPrecision Medicine Institute, University of Alabama at Birmingham, Birmingham, AL, USA.
Sree Deepthi MuthukrishnanThe Intellectual and Developmental Disabilities Research Center, The Semel Institute for Neuroscience and Human Behavior, and The Broad Stem Cell Research Center, The Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Sang Yul YuThe Intellectual and Developmental Disabilities Research Center, The Semel Institute for Neuroscience and Human Behavior, and The Broad Stem Cell Research Center, The Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Min Soo KimThe Intellectual and Developmental Disabilities Research Center, The Semel Institute for Neuroscience and Human Behavior, and The Broad Stem Cell Research Center, The Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-0462-8092
Alireza SohrabiDepartment of Bioengineering, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0001-8874-2268
Natalia P BiscolaDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Daisuke YamashitaDepartment of Neurosurgery, Ehime University Graduate School of Medicine, Shitsukawa 454, Toon, Ehime, Japan.
Ksenia S AnufrievaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine of Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia.
Tatyana F KovalenkoShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.
Grace JungDepartment of Medicine, Center for Iron Disorders, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Tomas GanzDepartment of Medicine, Center for Iron Disorders, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2830-5469
Beatrice O'BrienThe Intellectual and Developmental Disabilities Research Center, The Semel Institute for Neuroscience and Human Behavior, and The Broad Stem Cell Research Center, The Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Riki KawaguchiThe Intellectual and Developmental Disabilities Research Center, The Semel Institute for Neuroscience and Human Behavior, and The Broad Stem Cell Research Center, The Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Yue QinInterdepartmental Program in Bioinformatics, Program in Neurogenetics, Department of Neurology and Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Stephanie K SeidlitsDepartment of Bioengineering, University of Texas at Austin, Austin, TX, USA.
Alma L BurlingameDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8403-7307
Juan A Oses-PrietoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-4759-2341
Leif A HavtonDepartments of Neurology and Neuroscience, Icahn School of Medicine at Mount Sinai, James J Peters VA Medical Center, Bronx, NY, USA.
Steven A GoldmanCenter for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY, USA.ORCID http://orcid.org/0000-0002-5498-4303
Anita B HjelmelandDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0003-2200-3248
Ichiro NakanoDepartment of Neurosurgery, Harada Hospital, Iruma, Saitama, Japan. dr.ichiro.nakano@gmail.com.
Harley I KornblumThe Intellectual and Developmental Disabilities Research Center, The Semel Institute for Neuroscience and Human Behavior, and The Broad Stem Cell Research Center, The Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. hkornblum@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-3779-4540

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
UCLA IDDRC: Translational CoreP50HD103557 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Peyman Golshani, SUMA JACOB · 2020 to 2026
$9.6M
The unique roles of the GTP-binding/protein crosslinking enzyme transglutaminase-2 and signaling partners in aggressive cancersR01CA201402 · NCI · CORNELL UNIVERSITY · PI CERIONE, RICHARD A. · 2016 to 2024
$4.3M
Neural Progenitor Genes and Brain TumorsR01NS052563 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KORNBLUM, HARLEY IAN · 2006 to 2015
$2.4M
Metabolism Informs Intertumoral & Intratumoral HeterogeneityR01NS087913 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NAKANO, ICHIRO, RICH, JEREMY N · 2014 to 2018
$2.0M
Biosynthetic Metabolic Pathway Regulation of Glioma GrowthR01NS104339 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HJELMELAND, ANITA BORTON · 2018 to 2022
$1.9M
Tissue-Engineered Models of Microvessel-Mediated Glioblastoma InvasionR01CA241927 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI SEIDLITS, STEPHANIE KRISTIN · 2020 to 2024
$1.9M
TRANSCRIPTIONAL DETERMINANTS OF THE FATE TRAJECTORIES OF SINGLE HUMAN GLIAL PROGENITOR CELLS IN RESPONSE TO DEMYELINATION IN VIVOR01NS110776 · NINDS · UNIVERSITY OF ROCHESTER · PI GOLDMAN, STEVEN ALAN · 2019 to 2023
$1.8M
Novel role of compensatory proliferation in human brain tumorR01CA183991 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI NAKANO, ICHIRO · 2015 to 2019
$1.6M
Cell-intrinsic and contextual determinants of aging by human glial progenitor cellsR01AG072298 · NIA · UNIVERSITY OF ROCHESTER · PI GOLDMAN, STEVEN ALAN · 2021 to 2025
$1.6M
NCI NIH HHS P30 CA013148NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA183991NCI NIH HHS R01 CA201402NCI NIH HHS R01 CA241927NIA NIH HHS R01 AG072298NICHD NIH HHS P50 HD103557NINDS NIH HHS R01 NS052563NINDS NIH HHS R01 NS083767NINDS NIH HHS R01 NS087913NINDS NIH HHS R01 NS104339NINDS NIH HHS R01 NS110776NINDS NIH HHS R56 NS052563Russian Science Foundation (RSF) 24-15-00097U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA183991, R01CA201402U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) RO1CA241927U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) NS052563
6 · The paper itself

Abstract

Extensive neovascularization is a hallmark of glioblastoma (GBM). In addition to supplying oxygen and nutrients, vascular endothelial cells provide trophic support to GBM cells via paracrine signaling. Here we report that Endocan (ESM1), an endothelial-secreted proteoglycan, confers enhanced proliferative, migratory, and angiogenic properties to GBM cells and regulates their spatial identity. Mechanistically, Endocan exerts at least part of its functions via direct binding and activation of the PDGFRA receptor. Subsequent downstream signaling enhances chromatin accessibility of the Myc promoter and upregulates Myc expression inducing stable phenotypic changes in GBM cells. Furthermore, Endocan confers radioprotection on GBM cells in vitro and in vivo. Inhibition of Endocan-PDGFRA signaling with ponatinib increases survival in the Esm1 wild-type but not in the Esm1 knock-out mouse GBM model. Our findings identify Endocan and its downstream signaling axis as a potential target to subdue GBM recurrence and highlight the importance of vascular-tumor interactions for GBM development.

Indexed as

GlioblastomaNeoplasm ProteinsNeovascularization, PathologicProteoglycansReceptor, Platelet-Derived Growth Factor alphaSignal TransductionAnimalsBrain NeoplasmsCell Line, TumorCell MovementCell ProliferationEndothelial CellsGene Expression Regulation, NeoplasticHumansMiceMice, KnockoutESM1 protein, humanNeoplasm ProteinsProteoglycansReceptor, Platelet-Derived Growth Factor alpha

Identifiers

PMID39773984
PMCPMC11707362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.